Ipamorelin

6.2

Worth trying, BioHarmony verdict

BioHarmony score 6.2 out of 10

Ipamorelin is a selective growth-hormone secretagogue with strong receptor selectivity but almost no human efficacy data: its only completed human efficacy trial (postoperative ileus, n=114) failed, per Beck 2014.

Read full report

What is Ipamorelin?

Ipamorelin is a lab-made peptide that nudges your own pituitary to release a short pulse of growth hormone, and its biggest selling point is what it does not do. It is a selective agonist at the ghrelin receptor (GHS-R1a), and unlike the older peptides it replaced, it raises growth hormone without meaningfully spiking cortisol or prolactin, per Raun 1998. That clean profile is real and well-documented. The catch sits one layer down: almost none of the reasons people actually buy ipamorelin (fat loss, recovery, better sleep, anti-aging) have been tested in humans.

From the BioHarmony report, reviewed Sep 8, 2026.

Saved on this device only.

Safety watch-outs

  • New or worsening numbness or tingling (possible fluid-related nerve compression): reduce dose or stop.
  • Rising fasting glucose or HbA1c: stop and consult a clinician, especially with diabetes.
  • Any active or suspected cancer: do not use
  • growth-hormone-axis stimulation is contraindicated.

Full risk profile in the BioHarmony report.

Dosing as published

Source-reported figures only. This page does not calculate a personal dose.

No approved-label or study protocol is recorded for Ipamorelin yet.

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Educator coverage (4)

Attributed viewpoints, separate from primary research.

Trust & sourcing

  1. Last revieweddone
  2. Next reviewupcoming
US approvalNot FDA approved
CompoundingFDA Category 2 for 503B use

FDA places ipamorelin acetate in 503B Category 2 and identifies immunogenicity, impurity-characterization, and limited route-specific safety information.

Primary sources

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.